Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

Author(s): S. Tangri, C. LiCalsi, J. Sidney, A. Sette.

Journal Name: Current Medicinal Chemistry

Volume 9 , Issue 24 , 2002

Become EABM
Become Reviewer


One challenge associated with the clinical use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions. The molecular basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the

Keywords: epitope, immunostealth, antibody, htl

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [2191 - 2199]
Pages: 9
DOI: 10.2174/0929867023368647
Price: $58

Article Metrics

PDF: 12